INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
Trial details
- Registry ID
- NCT03037164
- Drugs studied
- Conventional (Control), INTERCEPT Blood System for Red Blood Cells
TrialRedline tracks 5 clinical trials sponsored by Cerus Corporation: 2 Phase 3, 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsNCT03037164 | Conventional (Control), INTERCEPT Blood System for Red Blood Cells | Completed | 2026-04-29Actual |
| Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery PatientsNCT03459287 | Control, INTERCEPT | Completed | 2023-12-04Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1NCT07015437 | INTERCEPT Blood System for RBCs, Infusion of autologous radiolabeled RBCs | Recruiting | 2026-12-15Estimated |
| Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCsNCT07152379 | 30-40 mL of INTERCEPT RBCs, ~30 mL of INTERCEPT RBCs plus plus 10 mL biotinylated INTERCEPT RBCs | Not yet recruiting | 2030-09-30Estimated |
| A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.NCT06697223 | INTERCEPT Blood System for Platelets with LED Illuminator | Completed | 2025-06-02Actual |
Names as written in the registry records.
NCT03037164 · Cerus Corporation
Before: Estimated. After: Actual.
Before: 31 Jul 2026. After: 29 Apr 2026.
Before: Active not recruiting. After: Completed.
Before: 10 participants (planned). After: 25 participants (planned).
Before: 1 Oct 2027. After: 30 Sep 2030.
NCT07015437 · Cerus Corporation
Before: 70 participants (planned). After: 120 participants (planned).
Before: 30 Jul 2026. After: 15 Dec 2026.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Post infusion recovery of Test platelets at end of 5 day storage Measure: Post infusion survival of Test platelets at end of 5 Day storage. After: Measure: Post Infusion Recovery of Test Platelets at End of 5 Day Storage Measure: Post Infusion Survival of Test Platelets at End of 5 Day Storage.
Before: Estimated. After: Actual.
Before: 60 participants (planned). After: 40 participants (actual).
Before: Estimated. After: Actual.
Before: Oct 2025. After: 2 Jun 2025.
Before: Not yet recruiting. After: Completed.